File Name
-
..——
-
125742_S1_M1_356h.pdf714.46KB2022-04-05 12:41:24125742_S1_M1_3674.pdf5.12MB2022-04-05 12:41:52125742_S1_M1_cover.pdf1.32MB2022-04-05 12:42:16125742_S1_M1_debarment.pdf656.42KB2022-04-05 12:42:38125742_S1_M1_exclusivity-claim.pdf616.11KB2022-04-05 12:43:00125742_S1_M1_fast-track-designation.pdf649.42KB2022-04-05 12:43:22125742_S1_M1_financial-cert-3454.pdf3.44MB2022-04-05 12:43:57125742_S1_M1_financial-cert-bias.pdf695.81KB2022-04-05 12:44:24125742_S1_M1_ipsp-agreed-letter.pdf657.84KB2022-04-05 12:44:51125742_S1_M1_priority-review-request-1.pdf2.37MB2022-04-06 14:14:12125742_S1_M1_priority-review-request.pdf1.59MB2022-04-05 12:41:08125742_S1_M1_trans-of-oblig.pdf717.14KB2022-04-05 12:46:29125742_S1_M1_us-agent-authorization.pdf1.03MB2022-04-05 12:46:58125742_S1_M1_userfee.pdf627.80KB2022-04-05 12:47:31125742_S1_M1_waiver-req-designated-suffix.pdf2.74MB2022-04-05 12:48:05125742_S1_M2_22_introduction.pdf670.17KB2022-04-05 12:48:54125742_S1_M2_24_nonclinical-overview.pdf1.61MB2022-04-05 12:50:25125742_S1_M2_26_pharmkin-tabulated-summary.pdf1.34MB2022-04-05 12:51:01125742_S1_M2_26_pharmkin-written-summary.pdf1.43MB2022-04-05 12:51:32125742_S1_M2_27_literature-references.pdf1.75MB2022-04-05 12:45:17125742_S1_M2_27_synopses-indiv-studies.pdf1.75MB2022-04-05 12:45:54125742_S1_M4_4223_185350.pdf1.40MB2022-04-05 12:56:00125742_S1_M4_4223_R-20-0072.pdf5.21MB2022-04-05 12:56:54125742_S1_M5_5351_c4591001-ad-hoc-label-tables.pdf889.15KB2022-04-05 12:57:24125742_S1_M5_5351_c4591001-fa-interim-compliance-sensitive.pdf1.26MB2022-04-05 13:03:51125742_S1_M5_5351_c4591001-fa-interim-compliance.pdf2.04MB2022-04-05 13:03:10125742_S1_M5_5351_c4591001-fa-interim-efficacy-response.pdf2.39MB2022-04-05 13:04:11125742_S1_M5_5351_c4591001-fa-interim-errata.pdf2.27MB2022-04-05 13:04:36125742_S1_M5_5351_c4591001-fa-interim-excluded-patients-sensitive.pdf15.70MB2022-04-05 12:53:49125742_S1_M5_5351_c4591001-fa-interim-excluded-patients.pdf1.81MB2022-04-05 13:05:03125742_S1_M5_5351_c4591001-fa-interim-lab-measurements-sensitive.pdf4.78MB2022-04-05 13:23:50125742_S1_M5_5351_c4591001-fa-interim-lab-measurements.pdf12.02MB2022-04-05 12:55:04125742_S1_M5_5351_c4591001-fa-interim-oversight-committees.pdf2.29MB2022-04-05 13:25:17125742_S1_M5_5351_c4591001-fa-interim-protocol.pdf31.31MB2022-04-05 13:07:47125742_S1_M5_5351_c4591001-interim-mth6-oversight-committees.pdf13.00MB2022-04-05 13:11:16125742_S1_M5_5351_c4591001-interim-mth6-protocol.pdf36.94MB2022-04-05 13:18:02125742_S1_M5_CRF_c4591001-1085-10851018.pdf2.25MB2022-04-05 13:39:53125742_S1_M5_CRF_c4591001-1085-10851116.pdf1.19MB2022-04-05 13:40:14125742_S1_M5_CRF_c4591001-1085-10851129.pdf1.94MB2022-04-05 13:40:43125742_S1_M5_CRF_c4591001-1085-10851216.pdf1.22MB2022-04-05 13:44:40125742_S1_M5_CRF_c4591001-1085-10851246.pdf1.14MB2022-04-05 13:43:05125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.pdf602.23KB2022-04-05 13:20:50125742_S1_M5_c4591001-A-adrg.pdf1.54MB2022-04-05 13:21:25125742_S1_M5_c4591001-A-bmi-12-15-scale.pdf627.05KB2022-04-05 13:21:55125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.pdf634.25KB2022-04-05 13:22:24125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.pdf620.20KB2022-04-05 13:22:54125742_S1_M5_c4591001-A-comorbidity-categories.pdf636.90KB2022-04-05 13:28:31125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.pdf606.89KB2022-04-05 13:29:00125742_S1_M5_c4591001-A-newlist-c4591001-6k-participants-enrolled-v3-17sep2020.pdf846.03KB2022-04-05 13:29:25125742_S1_M5_c4591001-A-report-cci-aids-hiv.pdf629.08KB2022-04-05 13:29:59125742_S1_M5_c4591001-A-report-cci-any-malignancy.pdf670.23KB2022-04-05 13:30:47125742_S1_M5_c4591001-A-report-cci-cerebrovascular.pdf631.62KB2022-04-05 13:25:57125742_S1_M5_c4591001-A-report-cci-chf.pdf628.18KB2022-04-05 13:26:31125742_S1_M5_c4591001-A-report-cci-dementia.pdf625.82KB2022-04-05 13:27:01125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.pdf625.67KB2022-04-05 13:27:28125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.pdf626.79KB2022-04-05 13:28:04125742_S1_M5_c4591001-A-report-cci-hemiplegia.pdf625.58KB2022-04-05 13:36:04125742_S1_M5_c4591001-A-report-cci-leukemia.pdf631.44KB2022-04-05 13:36:25125742_S1_M5_c4591001-A-report-cci-lymphoma.pdf640.12KB2022-04-05 13:36:49125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.pdf635.64KB2022-04-05 13:33:08125742_S1_M5_c4591001-A-report-cci-mi.pdf624.25KB2022-04-05 13:33:29125742_S1_M5_c4591001-A-report-cci-mild-liver.pdf628.36KB2022-04-05 13:33:53125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.pdf625.68KB2022-04-05 13:34:15125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.pdf624.81KB2022-04-05 13:34:34125742_S1_M5_c4591001-A-report-cci-periph-vasc.pdf631.60KB2022-04-05 13:34:57125742_S1_M5_c4591001-A-report-cci-pulmonary.pdf629.63KB2022-04-05 13:35:31125742_S1_M5_c4591001-A-report-cci-renal.pdf628.94KB2022-04-05 13:41:06125742_S1_M5_c4591001-A-report-cci-rheumatic.pdf629.40KB2022-04-05 13:41:26125742_S1_M5_c4591001-T-S-final-reacto-tables-track.pdf2.22MB2022-04-05 13:42:12125742_S1_M5_c4591001-T-S-roadmap.pdf702.77KB2022-04-05 13:42:41125742_S1_M5_c4591001-T-S-summary-differences-csr-vs-update.pdf666.79KB2022-04-05 13:37:33125742_S1_M5_c4591001-T-S-suppl-arg.pdf738.13KB2022-04-05 13:37:59125742_S1_M5_c4591001-T-S-updated-reacto-tlf.pdf17.43MB2022-04-05 13:39:24FDA-CBER-2021-5683-0021888-to-0021901_125742_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf1-sas.txt13.87KB2022-04-05 13:43:17FDA-CBER-2021-5683-0021902-to-0021915_125742_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf2-sas.txt14.67KB2022-04-05 13:43:24FDA-CBER-2021-5683-0021916-to-0021929_125742_S1_M5_c4591001-A-P-adae-s092-all-unb-p3-saf-sas.txt14.75KB2022-04-05 13:43:31FDA-CBER-2021-5683-0021930-to-0021943_125742_S1_M5_c4591001-A-P-adae-s092-cr-cut-p3x-saf-sas.txt15.11KB2022-04-05 13:43:36FDA-CBER-2021-5683-0021944-to-0021963_125742_S1_M5_c4591001-A-P-adae-sas.txt35.46KB2022-04-05 13:44:00FDA-CBER-2021-5683-0021964-to-0021980_125742_S1_M5_c4591001-A-P-adae-vax-tier2-p3-saf-sas.txt17.94KB2022-04-05 13:44:00FDA-CBER-2021-5683-0021981-to-0022027_125742_S1_M5_c4591001-A-P-adc19ef-sas.txt81.06KB2022-04-05 13:44:12FDA-CBER-2021-5683-0022028-to-0022040_125742_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-sg-eval-sas.txt19.55KB2022-04-05 13:44:16FDA-CBER-2021-5683-0022041-to-0022053_125742_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-wo-sg-eval-sas.txt19.46KB2022-04-05 13:46:43FDA-CBER-2021-5683-0022054-to-0022062_125742_S1_M5_c4591001-A-P-adc19ef-ve-sev-cov-pd1-aai-sas.txt12.27KB2022-04-05 13:46:47FDA-CBER-2021-5683-0022063-to-0022135_125742_S1_M5_c4591001-A-P-adce-s010-lr-p3-saf-sas.txt71.56KB2022-04-05 13:46:51FDA-CBER-2021-5683-0022136-to-0022325_125742_S1_M5_c4591001-A-P-adce-s020-se-p3-saf-sas.txt192.86KB2022-04-05 13:46:55FDA-CBER-2021-5683-0022326-to-0022345_125742_S1_M5_c4591001-A-P-adcevd-sas.txt27.11KB2022-04-05 13:47:00FDA-CBER-2021-5683-0022346-to-0022364_125742_S1_M5_c4591001-A-P-adcm-sas.txt32.19KB2022-04-05 13:46:21FDA-CBER-2021-5683-0022365-to-0022560_125742_S1_M5_c4591001-A-P-adds-s002-all-p3-rand-sas.txt155.76KB2022-04-05 13:46:25FDA-CBER-2021-5683-0022561-to-0022567_125742_S1_M5_c4591001-A-P-adds-sas.txt11.04KB2022-04-05 13:46:30FDA-CBER-2021-5683-0022568-to-0022600_125742_S1_M5_c4591001-A-P-adfacevd-sas.txt48.94KB2022-04-05 13:46:34FDA-CBER-2021-5683-0022601-to-0022617_125742_S1_M5_c4591001-A-P-admh-sas.txt24.03KB2022-04-05 13:46:38FDA-CBER-2021-5683-0022618-to-0022691_125742_S1_M5_c4591001-A-P-adsl-demo-7d-eval-eff-sas.txt74.64KB2022-04-05 13:48:01FDA-CBER-2021-5683-0022692-to-0022765_125742_S1_M5_c4591001-A-P-adsl-demo-7d-wwo-eval-eff-sas.txt74.71KB2022-04-05 13:47:04FDA-CBER-2021-5683-0022766-to-0022792_125742_S1_M5_c4591001-A-P-adsl-fu-d2-p3-saf-sas.txt29.20KB2022-04-05 13:47:08FDA-CBER-2021-5683-0022793-to-0022866_125742_S1_M5_c4591001-A-P-adsl-s005-demo-all-p3-saf-sas.txt75.39KB2022-04-05 13:47:12FDA-CBER-2021-5683-0022867-to-0023006_125742_S1_M5_c4591001-A-P-adsl-sas.txt197.17KB2022-04-05 13:47:43FDA-CBER-2021-5683-0023007-to-0023031_125742_S1_M5_c4591001-A-P-adsympt-sas.txt43.24KB2022-04-05 13:47:47FDA-CBER-2021-5683-0023032-to-0023065_125742_S1_M5_c4591001-A-P-adva-sas.txt44.80KB2022-04-05 13:47:51FDA-CBER-2021-5683-0023490-to-0023491_125742_S1_M5_c4591001-A-bmi-12-15-scale-1.xlsx12.98KB2022-04-05 13:48:07FDA-CBER-2021-5683-0023490-to-0023491_125742_S1_M5_c4591001-A-bmi-12-15-scale.xlsx12.98KB2022-04-05 13:47:55FDA-CBER-2021-5683-0023500-to-0023507_125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.xlsx28.74KB2022-04-05 13:51:36FDA-CBER-2021-5683-0023523-to-0023538_125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.xlsx18.48KB2022-04-05 13:51:45FDA-CBER-2021-5683-0023540_125742_S1_M5_c4591001-A-comorbidity-categories.xlsx18.86KB2022-04-05 13:51:50FDA-CBER-2021-5683-0023550-to-0023569_125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.xlsx22.28KB2022-04-05 13:51:55FDA-CBER-2021-5683-0023711-to-0023875_125742_S1_M5_c4591001-A-newlist-c4591001-6k-participants-enrolled-v3-17sep2020.xlsx84.13KB2022-04-05 13:52:00FDA-CBER-2021-5683-0023878_125742_S1_M5_c4591001-A-report-cci-aids-hiv.xlsx22.73KB2022-04-05 13:52:05FDA-CBER-2021-5683-0023895-to-0023915_125742_S1_M5_c4591001-A-report-cci-any-malignancy.xlsx34.78KB2022-04-05 13:52:10FDA-CBER-2021-5683-0023919-to-0023921_125742_S1_M5_c4591001-A-report-cci-cerebrovascular.xlsx12.44KB2022-04-05 13:52:24FDA-CBER-2021-5683-0023924_125742_S1_M5_c4591001-A-report-cci-chf.xlsx10.25KB2022-04-05 13:52:29FDA-CBER-2021-5683-0023926_125742_S1_M5_c4591001-A-report-cci-dementia.xlsx9.44KB2022-04-05 13:52:33FDA-CBER-2021-5683-0023928_125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.xlsx9.20KB2022-04-05 13:50:13FDA-CBER-2021-5683-0023930_125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.xlsx9.77KB2022-04-05 13:50:19FDA-CBER-2021-5683-0023932_125742_S1_M5_c4591001-A-report-cci-hemiplegia.xlsx9.58KB2022-04-05 13:50:23FDA-CBER-2021-5683-0023936-to-0023937_125742_S1_M5_c4591001-A-report-cci-leukemia.xlsx11.67KB2022-04-05 13:50:28FDA-CBER-2021-5683-0023944-to-0023950_125742_S1_M5_c4591001-A-report-cci-lymphoma.xlsx17.02KB2022-04-05 13:50:34FDA-CBER-2021-5683-0023955-to-0023958_125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.xlsx14.32KB2022-04-05 13:50:38FDA-CBER-2021-5683-0023960_125742_S1_M5_c4591001-A-report-cci-mi.xlsx8.90KB2022-04-05 13:50:43FDA-CBER-2021-5683-0023963_125742_S1_M5_c4591001-A-report-cci-mild-liver.xlsx10.35KB2022-04-05 13:50:47FDA-CBER-2021-5683-0023965_125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.xlsx9.20KB2022-04-05 13:50:52FDA-CBER-2021-5683-0023967_125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.xlsx9.15KB2022-04-05 13:50:57FDA-CBER-2021-5683-0023971-to-0023972_125742_S1_M5_c4591001-A-report-cci-periph-vasc.xlsx11.71KB2022-04-05 13:51:10FDA-CBER-2021-5683-0023975-to-0023976_125742_S1_M5_c4591001-A-report-cci-pulmonary.xlsx11.55KB2022-04-05 13:51:15FDA-CBER-2021-5683-0023979-to-0023980_125742_S1_M5_c4591001-A-report-cci-renal.xlsx11.09KB2022-04-05 13:51:20FDA-CBER-2021-5683-0023983-to-0023984_125742_S1_M5_c4591001-A-report-cci-rheumatic.xlsx23.94KB2022-04-05 13:51:26FDA-CBER-2021-5683-0023987_125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.xlsx21.34KB2022-04-05 13:51:32